Diffuse Large B-Cell Lymphoma, NOS · line 1 · Rituximab + CHOP (R-CHOP), 6 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-R-CHOP`

ID	`IND-DLBCL-1L-RCHOP`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-DLBCL-NOS`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard track for DLBCL 1L two-plan output (CHARTER §2). For relapsed/refractory after R-CHOP, treatment moves to 2L pathway (salvage chemo → autoSCT for fit; CAR-T for r/r refractory) — separate Indication entities.

Used By

Algorithms

ALGO-DLBCL-1L - ALGO-DLBCL-1L

Contraindications

CI-LVEF-LOW-FOR-ANTHRACYCLINE - CI-LVEF-LOW-FOR-ANTHRACYCLINE

Disease

DIS-FL - Follicular Lymphoma

Handbook Chapters

HB-DLBCL-1L - Diffuse large B-cell lymphoma: first-line reasoning

Handbook Questions

HQ-DLBCL-1L-001 - HQ-DLBCL-1L-001

Indication

IND-DLBCL-1L-POLA-R-CHP - IND-DLBCL-1L-POLA-R-CHP

Red flag

RF-DLBCL-INFECTION-SCREENING - Active or latent infection requiring resolution / prophylaxis before initiating R-CHOP-cl...